Ionis' Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Shots:
- The approval is based on P-III NEURO-TTR study trial assessing Tegsedi vs PBO in 172 patients in ratio (2:1) with hATTR amyloidosis with symptoms of polyneuropathy
- The study resulted in effective results in measures of neuropathy and QoL while measuring with a Neuropathy Impairment Score +7 (mNIS+7) & Norfolk QOL-DN total score with 80% reduction in TTR
- Tegsedi (inotersen) is a qw SC RNA-targeting drug used for the reduction in the production of TTR protein and has also received EU and Health Canada approval for 1 or stage 2 polyneuropathy in adult patients with hATTR. In April- 2018 Ionis granted Akcea worldwide rights to commercialize Tegsedi
Ref: Ionis | Image: USA today
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com